signs score have been similarly predictive of danger of developing PTS, suggesting that either alone may be made use of when assessing future risk of PTS.Ottawa Hospital Investigation Institute, Ottawa, Canada; 2Ostfold4Hospital, Ostfold, Norway; 3University of Western Ontario, London, Canada; Caspase Activator medchemexpress Dalhousie University, Halifax, Canada; McGill University, Montreal, Canada; 6University of Oslo, Oslo, Norway; 7McMaster University, Hamilton, Canada Background: Post-thrombotic syndrome (PTS) is one of the most frequent complication of venous thromboembolism (VTE). It has been postulated that rosuvastatin could protect against PTS by means of inhibiting expression of thrombus-associated mediators of inflammation. Aims: To explore in a multicenter randomized controlled trial if generic rosuvastatin can prevent PTS. Methods: 312 individuals receiving common anticoagulation for a newly diagnosed VTE had been randomly allocated to adjuvant rosuvastatin 20 mg when day-to-day for 180 days (n = 155) or no rosuvastatin (n = 157). In the finish from the trial, an independent observer who was blinded to study therapy performed a PTS assessment on each and every patient applying the Villalta scale. The primary clinical outcomes have been imply Villalta score and presence of PTS defined by Villalta score four at Day 180. Results: At Day 180, the Villalta score was three.five.three within the rosuvastatin arm vs. 3.3.3 within the manage arm (P = 0.59), and presence of PTS was in 29.7 the rosuvastatin arm vs. 25.5 in the control arm (P = 0.41). Secondary analyses showed no distinction between trial arms for presence of severe PTS (Villalta score 15) at Day 180 (2.0 vs. 2.7 , P = 1) and for modifications in Villalta score in between baseline and Day 180 (-3.7.four vs. -4.0.0, P = 0.59). Conclusions: This randomized controlled trial did not demonstrate efficacy of short-term use of rosuvastatin to stop PTS. Future research with longer rosuvastatin treatment are needed to exclude any advantage in preventing PTS. (NCT02679664)PB1151|Development of a brand new Disease-specific Healthrelated Excellent of Life Questionnaire following Deep Vein Thrombosis: Qualitative Phase of a Mixed Approach Development E. Asady1,two; W. Ghanima2,1,3; L.-P. Jelsness-Jorgensen2,four; F. Klok5; G.J. Boon5; H. Skuterud WikUniversity of Oslo, Oslo, Norway; two tfold Hospital Trust, Gr um,Norway; 3Oslo University Hospital, Oslo, Norway; 4 tfold University College, Halden, Norway; 5Leiden University Medical Center, Leiden, NetherlandsPB1150|Function of Individual Venous Symptoms and Signs at Baseline in Predicting Future Improvement of Post-thrombotic Syndrome: Sub-analysis from the ATTRACT Trial F. Rinfret1,2; C.-S. Gu3; S. Vedantham4; S. Kahn2,Background: A number of Health-related excellent of life (HRQoL) questionnaires for deep vein CB1 Inhibitor web Thrombosis (DVT) are offered. None of these have nonetheless been created in complete accordance with existing requirements for questionnaire development. Aims: To create a brand new disease-specific HRQoL questionnaire for DVT in accordance with state-of-the-art requirements, as defined by existing recommendations. Techniques: The questionnaire improvement was setup as a phase I-IV study, of which benefits from phase II are presented in this abstract. Phase II consisted of item generation by conducting interviews together with the target population. Accordingly, we carried out seven semistructured group interviews with 40 DVT patients, no less than 12 weeks soon after the acute occasion, in Norway along with the Netherlands. ThematicMcGill University, Montreal, Canada; 2Jewish Basic Hospital,Montreal, Canada; 3Centre for Regulatory